BIOSeedin Innovation Partnering Conference solidified its role as a nexus for global biopharma innovation, attracting more than 2,000 registrants from 10 countries. Senior executives and investors ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

The antidote market is witnessing substantial growth, largely propelled by the growing incidence of poisoning, drug overdoses, and snake or animal bites. This rising demand is supported by greater ...

Two drugs. Two strategies. One industry in the middle of a rewiring.

Ireland’s economy grew three times as rapidly as first estimated in the first quarter. That was driven by stockpiling of ...

Duchenne muscular dystrophy (DMD) has long been one of the most devastating genetic disorders to affect children. Marked by progressive muscle degeneration, early loss of mobility, and eventual ...

The digital pharmaceutical supply chain management market is projected to grow at a CAGR of 9% from 2025 to 2030. The growth ...

Adding niraparib to abiraterone acetate and prednisone may help slow cancer growth for patients with metastatic ...

The onychomycosis treatment products market is expected to reach USD 6,400.8 million by 2025 and is expected to steadily grow at a CAGR of 4.9% to reach USD 10,329.3 million by 2035. In 2024, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET.